{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:58:03Z","timestamp":1781672283959,"version":"3.54.5"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is rare, accounts for &amp;lt;1% of DLBCL, and is characterized by ALK rearrangement. ALK+ LBCL is a very aggressive disease with a poor prognosis, a high risk of relapse and a poor response to standard chemotherapy treatment, with a median overall survival of approximately one year in advanced-stage disease. The activity of ALK inhibitors in the treatment of relapsed\/refractory ALK+ LBCL is not well studied. Here, we report our experience with the use of alectinib in refractory ALK+ LBCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A previously healthy 14-year-old Saudi Arabian girl presented with progressive chest, loin, and iliac crest pain over two months, without B symptoms. Imaging revealed a left supradiaphragmatic soft tissue mass with supra and infradiaphragmatic nodal masses, pancreatic mass and right iliac bone aggressive lesion. Core biopsy of a left pararenal mass confirmed ALK-positive large B-cell lymphoma (ALK+ LBCL). Immunohistochemistry showed positivity for CD138, MUM1, CD79a (subset), CD4, EMA, CD45, CD10 (weak), BCL6, c-MYC, BCL2, and cytoplasmic ALK1. CD20 and PAX5 were negative. ALK rearrangement was confirmed by FISH; the bone marrow was not involved. Initial treatment with CHOEP failed, followed by progression on salvage ESHAP and IGEV chemotherapy. Radiation was given for bulky disease. Crizotinib was initiated with partial response but discontinued due to hepatotoxicity and disease progression. Alectinib was then started, resulting in a complete metabolic response (CMR). This was consolidated with an allogeneic stem cell transplant from a matched sibling donor, leading to a sustained CMR for 4 years with good tolerance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The use of next-generation ALK inhibitors in this case demonstrated excellent tolerability and induced sustained responses. This report suggests that alectinib may be an effective bridging therapy for refractory ALK+ LBCL to enable allogeneic SCT in selected patients. Further prospective studies are warranted to explore and optimize therapeutic strategies for this rare disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1844016","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:48:50Z","timestamp":1781671730000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Alectinib shows promise for the treatment of refractory ALK-positive large B-cell lymphoma: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Atheer","family":"Alsulami","sequence":"first","affiliation":[{"name":"Department of Adult Medical Oncology, Princess Noorah Oncology Center, King Abdulaziz Medical City","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roula","family":"Almufti","sequence":"additional","affiliation":[{"name":"Department of Adult Medical Oncology, King Faisal Specialist Hospital and Research Center","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleem","family":"Eldadah","sequence":"additional","affiliation":[{"name":"Department of Adult Hematology and Stem Cell Transplantation, Princess Noorah Oncology Center, King Abdulaziz Medical City","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya","family":"Al-Ghamdi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Umm Al-Qura University","place":["Makkah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.506","article-title":"Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification","volume":"2011","author":"Jaffe","year":"2011","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/PAS.0000000000000753","article-title":"ALK-positive large B-cell lymphoma: a clinicopathologic study of 26 cases with review of additional 108 cases in the literature","volume":"41","author":"Pan","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.21.5020","article-title":"Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis","volume":"27","author":"Laurent","year":"2009","journal-title":"J Clin Oncol"},{"key":"B5","volume-title":"WHO classification of tumor of hematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v86.5.1954.bloodjournal8651954","article-title":"Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM\/ALK: a distinct clinicopathologic entity","volume":"86","author":"Shiota","year":"1995","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1182\/blood.2022018145","article-title":"ALK-positive large B-cell lymphoma, a rare B-cell lymphoma expressing ALK","volume":"141","author":"Nahmod","year":"2023","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-11","article-title":"ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature","volume":"2","author":"Beltran","year":"2009","journal-title":"J Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800742","article-title":"ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature.","volume":"20","author":"Reichard","year":"2007","journal-title":"Mod Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00797-9","article-title":"ALK in cancer: From function to therapeutic targeting","volume":"25","author":"Voena","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0923-7534(20)33655-3","article-title":"Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response","volume":"92","author":"Wass","year":"2014","journal-title":"Eur J Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-07-0365","article-title":"Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma","volume":"6","author":"Christensen","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.70058","article-title":"Multi-institutional study of ALK-positive large B-cell lymphoma: Outcomes in the era of ALK inhibitors and biologically informed therapies","volume":"100","author":"Atallah-Yunes","year":"2025","journal-title":"Am J Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00488-x","article-title":"Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial","volume":"17","author":"Shaw","year":"2016","journal-title":"Lancet Oncol"},{"key":"B18","volume-title":"NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. Version 3.2026","year":"2026"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc1013224","article-title":"Crizotinib in anaplastic large-cell lymphoma","volume":"364","author":"Gambacorti-Passerini","year":"2011","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2015.1007862","article-title":"CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options","volume":"8","author":"Castillo","year":"2015","journal-title":"Expert Rev Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018436","article-title":"Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas","volume":"6","author":"Cerchietti","year":"2011","journal-title":"PloS One"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178416","article-title":"Anaplastic lymphoma kinase-positive large B-cell lymphoma: clinico-pathological study of 17 cases with review of literature","volume":"12","author":"Jiang","year":"2017","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-163386","article-title":"Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma\/leukemia","volume":"115","author":"Giuriato","year":"2010","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015443","article-title":"Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma","volume":"140","author":"Soumerai","year":"2022","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007537","article-title":"Durable responses with ALK inhibitors for primary refractory anaplastic lymphoma kinase-positive large B-cell lymphoma","volume":"7","author":"Takiar","year":"2023","journal-title":"Blood Adv"},{"key":"B26","article-title":"Promising response of anaplastic lymphoma kinase-positive large B-cell lymphoma to crizotinib salvage treatment: case report and review of literature","volume":"8","author":"Li","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1480880","article-title":"Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review","volume":"14","author":"Wang","year":"2024","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2023.2271212","article-title":"Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing","volume":"24","author":"Xia","year":"2023","journal-title":"Cancer Biol Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.014761","article-title":"ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions","volume":"95","author":"Van Roosbroeck","year":"2010","journal-title":"Haematologica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1844016\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:49:05Z","timestamp":1781671745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1844016\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":29,"alternative-id":["10.3389\/fonc.2026.1844016"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1844016","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1844016"}}